IL291386A - Targeted imaging of fibroblast activation protein and treatment of cancer and other lymphatic and inflammatory diseases - Google Patents
Targeted imaging of fibroblast activation protein and treatment of cancer and other lymphatic and inflammatory diseasesInfo
- Publication number
- IL291386A IL291386A IL291386A IL29138622A IL291386A IL 291386 A IL291386 A IL 291386A IL 291386 A IL291386 A IL 291386A IL 29138622 A IL29138622 A IL 29138622A IL 291386 A IL291386 A IL 291386A
- Authority
- IL
- Israel
- Prior art keywords
- fap
- fibrotic
- cancers
- therapy
- inflammatory diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901792P | 2019-09-17 | 2019-09-17 | |
| PCT/US2020/051328 WO2021055641A1 (en) | 2019-09-17 | 2020-09-17 | Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL291386A true IL291386A (en) | 2022-05-01 |
Family
ID=74883518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291386A IL291386A (en) | 2019-09-17 | 2022-03-15 | Targeted imaging of fibroblast activation protein and treatment of cancer and other lymphatic and inflammatory diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220409747A1 (https=) |
| EP (1) | EP4031184A4 (https=) |
| JP (2) | JP2022548155A (https=) |
| KR (1) | KR20220066098A (https=) |
| CN (1) | CN114901315B (https=) |
| AU (2) | AU2020348781B2 (https=) |
| BR (1) | BR112022005013A2 (https=) |
| CA (1) | CA3150890A1 (https=) |
| IL (1) | IL291386A (https=) |
| MX (1) | MX2022003215A (https=) |
| WO (1) | WO2021055641A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| US20230147962A1 (en) * | 2020-02-12 | 2023-05-11 | Philochem Ag | Fibroblast activation protein ligands for targeted delivery applications |
| EP4132921A4 (en) * | 2020-04-09 | 2024-03-27 | Purdue Research Foundation | Pi3 kinase inhibitors and uses thereof |
| WO2023244828A1 (en) * | 2022-06-17 | 2023-12-21 | Purdue Research Foundation | Fibroblast activation protein-targeted nanoparticle magnetic resonance imaging agents |
| AU2024235779A1 (en) * | 2023-03-10 | 2025-10-23 | Purdue Research Foundation | Bi-specific adapters and their use with universal car-t cells in the treatment of tumors and the inhibition of cancer-associated fibroblasts |
| WO2026041108A1 (zh) * | 2024-08-23 | 2026-02-26 | 苏州博锐创合医药有限公司 | 基于环肽和共价弹头的化合物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071787B2 (en) * | 2009-03-13 | 2011-12-06 | National Health Research Institutes | Pyrrolidine compounds |
| CN103788071A (zh) * | 2012-11-01 | 2014-05-14 | 中国人民解放军第二军医大学 | N-(5-(喹啉-6-基)吡啶-3-基)苯磺酰胺衍生物、制备方法及治疗用途 |
| AU2017213404A1 (en) * | 2016-01-29 | 2018-09-20 | Kyowa Kirin Co., Ltd. | Nucleic acid conjugate |
| CN116474108A (zh) * | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| EA202090776A1 (ru) * | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| US10966999B2 (en) * | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019154859A1 (en) * | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
| SG11202007180QA (en) * | 2018-02-06 | 2020-08-28 | Univ Heidelberg | Fap inhibitor |
| DE102018126558A1 (de) * | 2018-10-24 | 2020-04-30 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Markierungsvorläufer mit Quadratsäure-Kopplung |
-
2020
- 2020-09-17 WO PCT/US2020/051328 patent/WO2021055641A1/en not_active Ceased
- 2020-09-17 BR BR112022005013A patent/BR112022005013A2/pt unknown
- 2020-09-17 US US17/761,508 patent/US20220409747A1/en active Pending
- 2020-09-17 AU AU2020348781A patent/AU2020348781B2/en active Active
- 2020-09-17 CA CA3150890A patent/CA3150890A1/en active Pending
- 2020-09-17 KR KR1020227012076A patent/KR20220066098A/ko active Pending
- 2020-09-17 EP EP20865602.5A patent/EP4031184A4/en active Pending
- 2020-09-17 JP JP2022517166A patent/JP2022548155A/ja active Pending
- 2020-09-17 MX MX2022003215A patent/MX2022003215A/es unknown
- 2020-09-17 CN CN202080079485.1A patent/CN114901315B/zh active Active
-
2022
- 2022-03-15 IL IL291386A patent/IL291386A/en unknown
-
2025
- 2025-06-09 JP JP2025095652A patent/JP2025131780A/ja active Pending
-
2026
- 2026-02-10 AU AU2026200943A patent/AU2026200943A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN114901315B (zh) | 2025-04-29 |
| MX2022003215A (es) | 2022-04-25 |
| AU2020348781A1 (en) | 2022-04-14 |
| JP2022548155A (ja) | 2022-11-16 |
| BR112022005013A2 (pt) | 2022-06-21 |
| WO2021055641A1 (en) | 2021-03-25 |
| CN114901315A (zh) | 2022-08-12 |
| JP2025131780A (ja) | 2025-09-09 |
| EP4031184A4 (en) | 2023-12-06 |
| AU2026200943A1 (en) | 2026-02-26 |
| KR20220066098A (ko) | 2022-05-23 |
| CA3150890A1 (en) | 2021-03-25 |
| EP4031184A1 (en) | 2022-07-27 |
| AU2020348781B2 (en) | 2025-11-27 |
| US20220409747A1 (en) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291386A (en) | Targeted imaging of fibroblast activation protein and treatment of cancer and other lymphatic and inflammatory diseases | |
| IL291342A (en) | Tumor tissue disruption through fibroblast activation protein targeting | |
| IL291140A (en) | Preparations and methods for the treatment of inflammatory and immune diseases | |
| EP4034132A4 (en) | Erk5 degraders as therapeutics in cancer and inflammatory diseases | |
| EP4007640A4 (en) | CANCER COMBINATION THERAPY OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPY AGENTS | |
| IL290817A (en) | Methods for production of human recombinant arginase 1 and uses thereof | |
| GB201816383D0 (en) | Multimodal digital therapy and biometric analysis of biometric signals | |
| IL299695A (en) | Treatment of cancer, inflammatory diseases and autoimmune diseases | |
| IL315733A (en) | Compounds that Interact with RAS Superfamily Proteins for the Treatment of Cancer, Inflammatory, Basoplastic, and Fibrotic Diseases | |
| WO2019067984A3 (en) | Compositions that target tumor-associated macrophages and methods of use therefor | |
| HK40069456A (en) | Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases | |
| IL285268A (en) | Compositions and methods for treating neurocognitive disorders | |
| EP4096676A4 (en) | FIBROBLAST ACTIVATION PROTEIN (FAP) - TARGETED ANTIFIBROTIC THERAPY | |
| IL285663A (en) | Rodents with genetically engineered sodium channels and methods of using them | |
| ZA202105583B (en) | Methods of diagnosing and treating cervical cancer | |
| EP3960242A4 (en) | CONJUGATE AND CANCER THERAPEUTIC | |
| EP4058045A4 (en) | FIBROBLAST THERAPY AGAINST INFLAMMATORY BOWEL DISEASE | |
| HK40118314A (en) | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | |
| HK40074701A (en) | Modified grpr antagonist peptides for imaging and therapy of cancer | |
| HK40093390A (en) | Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | |
| HK40083657A (en) | Fibroblast activation protein(fap) - targeted antifibrotic therapy | |
| CA3291808A1 (en) | Methods and means for the treatment of chronic inflammatory and autoimmune disease | |
| IL285297A (en) | Compositions and methods for the treatment of constipation and other ailments of the gastrointestinal system | |
| HK40076276A (en) | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics | |
| HK40058933A (en) | Rodents having genetically modified sodium channels and methods of use thereof |